Quotient Sciences Header

Quotient Sciences Header

X

Find Approved Drugs for Cardiology/Vascular Diseases in Clinical Development in CANADA

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Dalton Pharma Services","sponsor":"Health Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dalton Expands Cannabinoids Capabilities","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Dalton Pharma Services"},{"company":"Correvio Pharma","sponsor":"Hong Kong Teson Pharma","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"$3.0 million","newsHeadline":"Correvio Partners with Hong Kong Teson Pharma Limited","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Correvio Pharma"},{"company":"Correvio Pharma","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"$76.0 million","newsHeadline":"Advanz Pharma Limited Closes Acquisition of Specialty Pharmaceutical Company Correvio Pharma Corp","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Correvio Pharma"},{"company":"Valeo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valeo Pharma\u2019s Redesca\u2122 Receives Positive Recommendation for Public Reimbursement in Quebec","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Biosimilar","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Valeo Pharma"},{"company":"Valeo Pharma","sponsor":"Group Purchasing Organizations","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valeo Pharma Obtains Listings for Redesca from Two GPO Representing 700 Hospitals and Healthcare Facilities Across Canada","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Valeo Pharma"},{"company":"Valeo Pharma","sponsor":"Desjardins Capital Markets","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Valeo Pharma Announces Upsize of Previously Announced Bought Deal Private Placement of Convertible Debentures to $15 Million With Concurrent $10 Million Private Placement From Investissement Quebec","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Valeo Pharma"},{"company":"Teligent, Inc","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"$45.8 million","upfrontCash":"Undisclosed","newsHeadline":"Hikma Expands Into Canada with Acquisition of Teligent Sterile Injectable Assets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Teligent, Inc"}]

Teligent, Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Hikma Expands Into Canada with Acquisition of Teligent Sterile Injectable Assets

Details:

The acquisition marks Hikma’s expansion into Canada and a portfolio of 25 sterile injectable products including the marketed product Atropine-G, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approved by Health Canada.

Lead Product(s): Atropine

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atropine-Generic

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

Deal Size: $45.8 million Upfront Cash: Undisclosed

Deal Type: Acquisition January 17, 2022

ASK
US

Upload
your Pipeline Activity

Valeo Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Valeo Pharma Announces Upsize of Previously Announced Bought Deal Private Placement of Convertible Debentures to $15 Million With Concurrent $10 Million Private Placement F...

Details:

The net proceeds of the Offering and Concurrent Private Placement will be used to support commercial efforts related to the recently launched products (Redesca™, Enerzair®, and Atectura®).

Lead Product(s): Heparin Sodium

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Redesca

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Desjardins Capital Markets

Deal Size: $10.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement November 24, 2021

ASK
US

Upload
your Pipeline Activity

Valeo Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Valeo Pharma Obtains Listings for Redesca from Two GPO Representing 700 Hospitals and Healthcare Facilities Across Canada

Details:

Under the terms of the contracts, the GPOs have listed Redesca™ and Redesca HP™, Valeo’s leading low molecular weight heparin (“LMWH”) biosimilar, as well as three other hospital products (Amikacin, Ethacrynate Sodium and Benztropine), for a 3-year period.

Lead Product(s): Heparin Sodium

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Redesca

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Group Purchasing Organizations

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement October 13, 2021

ASK
US

Upload
your Pipeline Activity

Valeo Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Valeo Pharma’s Redesca™ Receives Positive Recommendation for Public Reimbursement in Quebec

Details:

Redesca™ is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism.

Lead Product(s): Enoxaparin Sodium

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Redesca

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 25, 2021

ASK
US

Upload
your Pipeline Activity

Correvio Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Advanz Pharma Limited Closes Acquisition of Specialty Pharmaceutical Company Correvio Pharma Corp

Details:

Advanz Pharma believes that Correvio's niche portfolio, consisting of an established brand, and two growing, patent-protected brands, plus a pipeline of potential product launches, are highly complementary to its current priorities and future focus.

Lead Product(s): Vernakalant Hydrochloride

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Advanz Pharma

Deal Size: $76.0 million Upfront Cash: $76.0 million

Deal Type: Acquisition May 27, 2020

ASK
US

Upload
your Pipeline Activity

Correvio Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Correvio Partners with Hong Kong Teson Pharma Limited

Details:

The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.

Lead Product(s): Tirofiban

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Hong Kong Teson Pharma

Deal Size: $3.5 million Upfront Cash: $3.0 million

Deal Type: Agreement March 10, 2020

ASK
US

Upload
your Pipeline Activity

Dalton Pharma Services

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Dalton Expands Cannabinoids Capabilities

Details:

Dalton receives the license amendment from Health Canada under Cannabis regulations enabling transfer of finished cGMP cannabis products to licensed dealers.

Lead Product(s): Cannabidiol

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Health Canada

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 15, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY